Background: Persistent diarrhea (PD) is a common disease in childhood worldwide. Clinical studies suggested that zinc supplementation is useful in most PD children. However, the relationship between the zinc and immune status of the PD children has not been reported. Objective: To examine serum zinc levels and immune status in 6 to 24 months old children with PD before and after 120 days of oral zinc supplementation and to evaluate the effects of zinc supplementation on serum zinc levels and immune status in PD children. Methods: A case control study was carried. Fifty-eight children aged 6 to 24 months with PD were enrolled. 58 patients were divided into two groups, zinc group (28 cases) and control group (30 cases). Laboratory investigation of serum zinc levels, Lymphocyte subsets (CD3+%, CD4+%, CD8+% and CD4+/CD8+ ratio) and immunoglobulins (IgG, IgA and IgM) levels was carried out in all these patients once at enrollment and again after 120 days of treatment. Results: Before treatment, the serum zinc concentration was 4.37 ± 1.23 μmol/L in zinc group and 4.42 ± 1.45 μmol/L in control group ( P > 0.05). However, after treatment, the serum zinc concentrations in the zinc group were significantly higher (8.81 ± 2.56 μmol/L), as compared to the control group (4.12 ± 1.02 μmol/L) ( P < 0.05). Regarding immune status, Lymphocyte subsets CD3+%, CD4+%, CD8+% and CD4+/CD8+ ratio and IgG, IgA and IgM levels of all the children with PD were measured once at enrollment and again after 120 days of treatment. There were no significant differences between the zinc and the control groups in CD3+%, CD4+%, CD8+% and CD4+/CD8+ ratios ( P > 0.05) before giving treatment. However, after 120 days of treatment, in the zinc group there was a significant rise in CD4+% (53.60 ± 5.78). The CD4 was significantly higher in the zinc group as compared to the control group (44.73 ± 4.39) ( P < 0.05). Besides CD4+%, the CD4+/CD8+ ratio was also found to be higher among zinc group (1.49 ± 0.29) as compared to the control group (1.26 ± 0.18) after treatment ( P < 0.05). But there were no statistically significant differences in CD3+% and CD8+% between zinc and control group after treatment ( P > 0.05). Regarding immunoglobulins, there were no significant differences between zinc and control group in IgG, IgA and IgM levels ( P > 0.05) at the time of enrollment (before treatment). However, after treatment, the mean IgG levels in zinc group and control group were 6.36 ± 0.95 g/l and 5.67 ± 0.74 g/l, respectively, P < 0.05. Similarly, after treatment, IgM levels in the zinc group were found significantly higher (1.58 ± 0.13 g/l), as compared to the control group (1.43 ± 0.20 g/l) ( P < 0.05) but no significant differences in IgA levels were evident between the two groups after treatment. Conclusion: Administration of oral zinc supplement improved both serum zinc levels and immune status in children with PD. Zinc supplementation should be administered as adjunctive therapy for PD children.
Diarrhea is a major health problem in pediatrics worldwide. It is the second leading cause of death of children in developing countries and contributes to 1.5 - 2.5 million deaths annually in children under the age of five [
As the onset of PD is most often at a critical stage of physical and mental development, it can have a serious adverse impact on growth curves, intellectual and cognitive function, and future educational performance, and can also increase morbidity and mortality due to other diseases [
Patients attending the pediatric outpatient department or admitted in the inpatient wards of First Affiliated Hospital of Yangtze University, fulfilling the inclusion criteria were evaluated clinically with detailed history, physical examination and laboratory investigations. The study was conducted from December 2017 to December 2018.
The study protocol was approved by the Ethics Committee of the People’s First Hospital of Jingzhou Affiliated to Yangtze University.
Inclusion criteria: Patients aged 6 to 24 months with a diagnosis of persistent diarrhea (Lasting 14 days or more) were selected.
Exclusion criteria: Children known to have Pneumonia, severe malnutrition, Measles, Malaria, TB, HIV, AIDS, Meningitis, UTI, Hepatitis, Hyperthyroidism, Hypothyroidism, Epilepsy, and other diseases. Genetic and metabolic disorders. The children taking zinc compounds. Known allergy or intolerance to zinc or zinc containing products. Refused consent.
Fifty-eight patients with PD were enrolled and divided into two groups. Zinc group and control group, in zinc group, patients were treated with antibiotics, ORS and zinc supplementation. Control groups were treated with antibiotics and ORS without zinc supplementation.
After detailed physical examination, laboratory investigation of serum zinc levels, lymphocyte subsets CD3, CD4, CD8 and immunoglobulins-IgG, IgA, IgM levels were carried out in all the patients with PD before and after 120 days of treatment.
For the zinc analysis, 3 ml of venous blood from each patient was collected aseptically into plastic tubes (Nalgene Sybron Corporation, Rockester, New York) and centrifuged within one hour to avoid haemolysis. The serum obtained was frozen at −20˚C until the zinc analysis. Serum zinc levels were measured with atomic absorption spectrometry (AAS) [
CD3, CD4, CD8 and Immunoglobulins-IgG, IgA, IgM levels: 2 ml of fresh venous blood was collected aseptically in heparin-coated sterile vials (Vacutainer system; Becton Dickinson, Rutherford, NY). Whole blood samples were analyzed with a Multi-Q-Prep processor (Beckman Coulter, FL, USA) and then the Epics-XL (Beckman Coulter) flow cytometer. Lymphocytes were analyzed using a gate set on forward scatter versus side scatter, and a three-color flow cytometry combination reagent of CD3, CD4 and CD8. Anti-human monoclonal antibodies CD3-PE-CY5/CD4-FITC/CD8-PE were from Immunotech, Ltd, MO, USA. For each sample, the detection was analysed with the CELLQuest software (Beckman Coulter). The results were expressed as the percentages of CD3+, CD4+ and CD8+ cells.
The concentrations of total IgG, IgA and IgM in serum were determined by immunoturbidimetric assay [
Oral zinc supplementation was only administered to 28 persistent diarrhea cases along with other treatment (treatment with ORS, and antibiotics) whereas the control groups were only treated with ORS and antibiotics but not given zinc supplementation. The zinc preparation contained zinc gluconate (0.5 mg/10ml) in syrup form manufactured by Harbin Pharmaceutical Group in Harbin, China. A fixed dose of zinc syrup 10 ml bid daily was administered to the children aged < 1 year and 10 ml tid daily to the children aged > 1 year for 120 days since the time of enrollment. A repeat full dose was given if the child vomited within an hour of taking the treatment.
SPSS.20.0 software was used in this study for statistical analysis and data processing. The comparison between the groups was done using independent t-test. All the measurement data were expressed as mean ± standard deviation. P-values < 0.05 were considered statistically significant.
A total of 58 children diagnosed with persistent diarrhea were enrolled in the study, of which 28 patients were allocated to zinc group and 30 patients to control group. Children with PD treated with antibiotics, ORS and zinc supplementation were selected as zinc group, whereas children with PD treated with antibiotics and ORS without zinc supplementation were selected as control group. Out of 58 subjects, total males among zinc and control group were 12 (42.86%) and 16 (53.33%), respectively, whereas, total females among zinc and control group were 16 (57.14%) and 14 (46.67%), respectively.
The children selected for the study were between 6 to 24 months of age with the mean age of 14.82 ± 5.86 months in zinc group and 14.23 ± 5.48 months in control group. There was no statistically significant difference in age between the two groups (P > 0.05).
In a sample of 58 selected children with PD (zinc group 28, control group 30), serum zinc levels were measured once at enrollment and again after 120 days of treatment. The serum zinc levels at baseline (before treatment) and after treatment were then compared between the zinc and control groups.
At baseline, the mean serum zinc concentration was 4.37 ± 1.23 μmol/L in zinc group and 4.42 ± 1.45 μmol/L in control group (P > 0.05).
However, after treatment the serum zinc concentrations in the zinc group was significantly higher (8.81 ± 2.56 μmol/L), as compared to the control group (4.12 ± 1.02 μmol/L) (P < 0.05) as shown in
Lymphocyte Subset Results
In a sample of 58 selected children with PD (zinc 28, control 30), lymphocyte subsets (CD3+%, CD4+%, CD8+% and CD4+/CD8+ ratio) were measured once at enrollment and again after 120 days of treatment.
Before treatment, there were no significant differences between the zinc and the control groups in CD3+%, CD4+%, CD8+% and CD4+/CD8+ ratios (P > 0.05). However, after treatment, in the zinc group there was a significant rise in CD4+% (53.60 ± 5.78). The CD4 rise was significantly higher in the zinc group as compared to the control group (44.73 ± 4.39) which was statistically evident (P < 0.05). Besides CD4+%, the CD4+/CD8+ ratio was also found to be higher among zinc group (1.49 ± 0.29) as compared to the control group (1.26 ± 0.18) after treatment, as showed in
Immunoglobulin Results
The immunoglobulin levels, IgG, IgA and IgM of all the 58 selected children with PD (zinc 28, control 30) were measured once at enrollment and again after 120 days of treatment. The data were showed in
| Serum zinc (μmol/L) | Zinc group (n = 28) | Control group (n = 30) | P value |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| Before treatment | 4.37 ± 1.23 | 4.42 ± 1.45 | 0.246 |
| After treatment | 8.81 ± 2.56 | 4.12 ± 1.02 | 0.001 |
| Cell subsets | Sample collection | Zinc group (n = 28) | Control group (n = 30) | P value |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||
| CD3+% | Before | 64.88 ± 6.66 | 64.22 ± 5.49 | 0.485 |
| After | 62.99 ± 10.93 | 65.44 ± 5.52 | 0.436 | |
| CD4+% | Before | 44.25 ± 4.66 | 44.40 ± 4.54 | 0.578 |
| After | 53.60 ± 5.78 | 44.73 ± 4.39 | 0.001 | |
| CD8+% | Before | 37.75 ± 5.09 | 38.07 ± 5.00 | 0.612 |
| After | 36.42 ± 5.07 | 36.51 ± 4.08 | 0.523 | |
| CD4+/CD8+ | Before | 1.18 ± 0.13 | 1.18 ± 0.12 | 0.613 |
| After | 1.49 ± 0.29 | 1.26 ± 0.18 | 0.002 |
| Immuno-globulins (g/l) | Sample collection | Zinc group (n = 28) | Control group (n = 30) | P value |
|---|---|---|---|---|
| Mean ± SD | Mean ± SD | |||
| IgG | Before | 5.49 ± 0.72 | 5.48 ± 0.73 | 0.428 |
| After | 6.36 ± 0.95 | 5.67 ± 0.74 | 0.003 | |
| IgA | Before | 0.43 ± 0.06 | 0.41 ± 0.06 | 0.341 |
| After | 0.76 ± 0.09 | 0.75 ± 0.09 | 0.411 | |
| IgM | Before | 1.18 ± 0.19 | 1.23 ± 0.17 | 0.231 |
| After | 1.58 ± 0.13 | 1.43 ± 0.20 | 0.012 |
In developing countries, diarrhoea causes around 500,000 child deaths annually. Zinc supplementation during acute diarrhoea is currently recommended by the World Health Organization (WHO) and the United Nations Children’s Fund (UNICEF). There are fewer data about zinc supplementation in PD children. We firstly investigate the relationship between the zinc supplementation and immune status in PD children and suggest that zinc supplementation improves the immune status and is beneficial in for the PD children.
There are several different mechanism of action of zinc on acute diarrhoea. Zinc influences the activity of over 300 enzymes, some of which are responsible for DNA replication and transcription. Zinc promotes immunity, skin and mucosal resistance to infection, growth, and development of the nervous system. It is also an important antioxidant and preserves cellular membrane integrity. At the level of gastrointestinal system, zinc restores mucosal barrier integrity and enterocyte brush-border enzyme activity, it promotes the production of antibodies and circulating lymphocytes against intestinal pathogens.
Most studies about zinc supplementation are acute diarrhea in children. In the present case control study, we examined the effects of zinc supplementation PD children. Here, we investigated the effects of zinc supplementation on serum zinc levels, cell mediated immune status and humoral immune status in young children with PD. Children under zinc group received zinc supplementation in addition to antibiotics and ORS, whereas those under control group received only antibiotics and ORS. This is also a vulnerable time as the babies own antibodies and immunity have yet to develop and the maternal antibodies start to decrease in a child’s body [
Zinc concentration can be assessed in plasma, hair and urine in detecting zinc deficient states but measuring the serum zinc level has been recommended as an appropriate biomarker [
At the time of enrollment, the serum zinc concentration was 4.37 ± 1.23 μmol/L in zinc group and 4.42 ± 1.45 μmol/L in control group with a P-value of >0.05 showing no statistically significant difference between zinc and control group in serum zinc concentrations. However, after treatment the serum zinc concentrations in the zinc group was significantly higher (8.81 ± 2.56 μmol/L), as compared to the control group (4.12 ± 1.02 μmol/L). Therefore, children who were not given zinc supplements generally had stable or declining serum zinc concentrations probably reflecting net loss of zinc during diarrhea which is supported by the Castillo-Duran C et al. [
In the present study, oral zinc supplementation for 120 days improved the parameters of both cell-mediated and humoral immunity among zinc groups. Whereas, in control groups, there was deterioration of immune status. The deterioration of immune status in children between baseline and 120 days is consistent with the finding of worsening zinc status between baseline and 120 days in the unsupplemented group. It is clear from many studies that zinc affects multiple aspects of the immune system, from the barrier of the skin to gene regulation within lymphocytes [
In the present study, zinc supplementation improved the important classic parameters of cell-mediated immune competence the number of circulating T-lymphocytes, especially CD4+ cells percentage and the ratio of CD4+/CD8+ with no statistically significant difference in CD3+% and CD8+%. These findings are consistent with the study done by Sunil S et al. [
Regarding humoral immunity, the present study showed improvement in IgG, and IgM levels with no statistically significant difference in IgA levels following 120 days of oral zinc supplementation among zinc groups. Our findings are comparable with the study done by Muhammad J, et al. [
Results of the study suggest that zinc supplementation may provide significant nutritional, immunological and clinical benefits to children during the episodes of PD. Moreover, zinc used as a treatment for diarrhea reduces mortality in children.
The role of zinc in diarrhea may be mediated through several mechanisms. The possible mechanisms for the effect of zinc supplementation on diarrhea include improved intestinal absorption of water and electrolytes, quicker regeneration of the gut epithelium, increased levels of enterocyte brush border enzymes, and improved immune responses. This is thought to lead to rapid clearance of diarrheal pathogens from the intestine [
The administration of zinc supplement in the PD children of age from 6 to 24 months for 120 days has a beneficial effect. In the present study, children who received zinc supplements showed a marked improvement in serum zinc levels and immunological parameters particularly CD4+%, CD4+/CD8+ ratio and IgG and IgM levels, suggesting that zinc supplementation has a significant positive effect on serum zinc levels and immune status. So, here we conclude that oral zinc supplementation is a simple and effective therapeutic intervention in the management of persistent diarrhea. Thus, we recommend the use of zinc supplement as adjunctive therapy in all the episodes of diarrhea to improve the management of diarrhea [
The authors declare no conflicts of interest regarding the publication of this paper.
Jiang, Y.F., Mandal, K. and Lu, H.Z. (2021) Serum Zinc Levels and Immune Status of Children with Persistent Diarrhea Following Oral Zinc Supplementation. Yangtze Medicine, 5, 33-42. https://doi.org/10.4236/ym.2021.51004